Halozyme Therapeutics Bids to Acquire German Competitor Evotec

Dow Jones

Nov 15, 2024

By Sabela Ojea

Halozyme Therapeutics submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.)

The San Diego-based biopharmaceutical company on Thursday said it is proposing to acquire competitor Evotec for EUR11 per share, representing a 109% premium to its share price on Oct. 15, the day prior to a report on Triton Partners' stake in Evotec.

Halozyme Chief Executive Helen Torley said the acquisition would create a U.S., European innovative services company that would accelerate the discovery and development of a diverse pipeline of treatments.

The company added that the takeover wouldn't be subject to any financing contingency, as it has significant cash reserves on-hand and a strong balance sheet.

Halozyme's M&A disclosure came shortly after Bloomberg reported earlier this week that Triton Partners was considering a takeover bid for Evotec, citing people familiar with the matter.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

November 14, 2024 17:20 ET (22:20 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2483562493"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2483562493\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2483562493?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-15 06:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483562493","market":"other","top_or_hot":-1,"title":"Halozyme Therapeutics Bids to Acquire German Competitor Evotec","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Halozyme <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.) \n</p>\n<p>\n  The San Diego-based biopharmaceutical company on Thursday said it is proposing to acquire competitor Evotec for EUR11 per share, representing a 109% premium to its share price on Oct. 15, the day prior to a report on Triton Partners' stake in Evotec. \n</p>\n<p>\n  Halozyme Chief Executive Helen Torley said the acquisition would create a  U.S., European innovative services company that would accelerate the discovery and development of a diverse pipeline of treatments. \n</p>\n<p>\n  The company added that the takeover wouldn't be subject to any financing contingency, as it has significant cash reserves on-hand and a strong balance sheet. \n</p>\n<p>\n  Halozyme's M&amp;A disclosure came shortly after Bloomberg reported earlier this week that Triton Partners was considering a takeover bid for Evotec, citing people familiar with the matter. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 14, 2024 17:20 ET (22:20 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Halozyme Therapeutics Bids to Acquire German Competitor Evotec</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHalozyme Therapeutics Bids to Acquire German Competitor Evotec\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-15 06:20</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Halozyme <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.) \n</p>\n<p>\n  The San Diego-based biopharmaceutical company on Thursday said it is proposing to acquire competitor Evotec for EUR11 per share, representing a 109% premium to its share price on Oct. 15, the day prior to a report on Triton Partners' stake in Evotec. \n</p>\n<p>\n  Halozyme Chief Executive Helen Torley said the acquisition would create a  U.S., European innovative services company that would accelerate the discovery and development of a diverse pipeline of treatments. \n</p>\n<p>\n  The company added that the takeover wouldn't be subject to any financing contingency, as it has significant cash reserves on-hand and a strong balance sheet. \n</p>\n<p>\n  Halozyme's M&amp;A disclosure came shortly after Bloomberg reported earlier this week that Triton Partners was considering a takeover bid for Evotec, citing people familiar with the matter. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 14, 2024 17:20 ET (22:20 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2483562493","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483562493","pubTimestamp":1731622800,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Halozyme Therapeutics submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros . The San Diego-based biopharmaceutical company on Thursday said it is proposing to acquire competitor Evotec for EUR11 per share, representing a 109% premium to its share price on Oct. 15, the day prior to a report on Triton Partners' stake in Evotec.Halozyme Chief Executive Helen Torley said the acquisition would create a  U.S., European innovative services company that would accelerate the discovery and development of a diverse pipeline of treatments.The company added that the takeover wouldn't be subject to any financing contingency, as it has significant cash reserves on-hand and a strong balance sheet.Halozyme's M&A disclosure came shortly after Bloomberg reported earlier this week that Triton Partners was considering a takeover bid for Evotec, citing people familiar with the matter.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","HALO":"奥洛兹美医疗"},"translate_title":"Halozyme Therapeutics竞购德国竞争对手Evotec","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":1},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Halozyme Therapeutics submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.) \n\n\n  The San Diego-based biopharmaceutical company on Thursday said it is proposing to acquire competitor Evotec for EUR11 per share, representing a 109% premium to its share price on Oct. 15, the day prior to a report on Triton Partners' stake in Evotec. \n\n\n  Halozyme Chief Executive Helen Torley said the acquisition would create a  U.S., European innovative services company that would accelerate the discovery and development of a diverse pipeline of treatments. \n\n\n  The company added that the takeover wouldn't be subject to any financing contingency, as it has significant cash reserves on-hand and a strong balance sheet. \n\n\n  Halozyme's M&A disclosure came shortly after Bloomberg reported earlier this week that Triton Partners was considering a takeover bid for Evotec, citing people familiar with the matter. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2024 17:20 ET (22:20 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}